Publication | Open Access

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

ChromatinTumor BiologyOncologyDeacetylase InhibitorFoxo3-mediated Bim1 ExpressionMedicineChromatin RemodelingBreast CancerRadiation OncologyCancer BiologyCell BiologyCancer ResearchLapatinib Efficacy